ClinicalTrials.gg
CompletedNCT06601504Updated Sep 24, 2026

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

A Phase 2 interventional study of HMPL-760 planned dose 1 and R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, sponsored by Hutchmed. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Hutchmed · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China — 143 open to participants now, 165 under way, 31 of them phase 3. Lymphoma, Large B-Cell, Diffuse · China.

Enrollment
133rd of 277
61 · median 59
Started
2024
with 28 others
Phase 2
114 of 306
63 open now
Registered
225th of 306
by date

Among the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, this one is the 133rd largest by enrollment of the 277 interventional ones that give a count, is one of 29 that started in 2024, is one of 114 in phase 2, and was the 225th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

143 of the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

Read the detailed description

A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination with R-GemOx versus Placebo in Combination with R-GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Keywords

  • R-GemOx
  • R/R DLBCL
  • HMPL-760
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form(ICF) and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. (ECOG) performance status between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally ;
  7. Expected survival is more than 12 weeks;

Exclusion criteria

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with (HIV), virus (HBV), or virus (HCV):
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. Toxicities from prior anticancer therapy not resolved to Grade ≤ 1 (except for alopecia and decreased appetite);
  8. active infection;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Group A: HMPL-760 planned dose 1 once daily (QD) in combination with R-GemOx regimen

    Group A: Patients will receive HMPL-760 planned dose 1 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

    Drug: HMPL-760 planned dose 1 · Drug: R-GemOx

  • Placebo comparator
    Group B: HMPL-760 placebo planned dose 1 once daily (QD) in combination with R-GemOx regimen

    Patients will receive HMPL-760 placebo planned dose 1 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

    Drug: R-GemOx · Drug: HMPL-760 placebo planned dose 1

  • Experimental
    Group C: HMPL-760 planned dose 2 once daily (QD) in combination with R-GemOx regimen

    Patients will receive HMPL-760 planned dose 2 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

    Drug: R-GemOx · Drug: HMPL-760 planned dose 2

  • Placebo comparator
    Group D: HMPL-760 placebo planned dose 2 once daily (QD) in combination with R-GemOx regimen

    Patients will receive HMPL-760 placebo planned dose 2 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

    Drug: R-GemOx · Drug: HMPL-760 placebo planned dose 2

Interventions

  • HMPL-760 planned dose 1 daily (QD) orally

  • DrugR-GemOx

    R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.

    Also known as: Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection

  • DrugHMPL-760 placebo planned dose 1

    HMPL-760 placebo planned dose 1 daily (QD) orally

  • HMPL-760 planned dose 2 daily (QD) orally

  • DrugHMPL-760 placebo planned dose 2

    HMPL-760 placebo planned dose 2 daily (QD) orally

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS): Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR), as assessed by investigator.

    Time frame: Up to approximately 2 years

  2. Complete response (CR) rate

    Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR), as assessed by investigator.

    Time frame: Up to approximately 2 years

  3. Duration of response (DoR)

    For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first, as assessed by investigator.

    Time frame: Up to approximately 2 years

  4. Clinical benefit rate (CBR)

    Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD).

    Time frame: Up to approximately 2 years

  5. Time to response (TTR)

    Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR), as assessed by investigator.

    Time frame: Up to approximately 2 years

  6. Overall survival (OS)

    Overall Survival (OS) is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 2 years

  7. Safety Endpoints of adverse events

    Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of serious adverse events (SAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).

    Time frame: Up to approximately 2 years

  8. Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx

    Trough plasma concentration (Ctrough) of drug

    Time frame: At the end of Cycle 7 (each cycle is 21 days)

  9. Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx

    Maximum observed concentration, occurring at time Tmax at steady-state (Cmax,ss) of drug

    Time frame: At the end of Cycle 7 (each cycle is 21 days)

  10. Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx

    Time of maximum observed concentration at steady-state(Tmax,ss) of drug

    Time frame: At the end of Cycle 7 (each cycle is 21 days)

  11. Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx

    The partial area from dosing time to dosing time plus Tau at steady-state (AUCss) of drug

    Time frame: At the end of Cycle 7 (each cycle is 21 days)

  12. Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx

    Apparent clearance at steady-state (CLss/F) of drug (if applicable)

    Time frame: At the end of Cycle 7 (each cycle is 21 days)

  13. Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx

    Apparent volume of distribution at steady-state (Vz,ss/F) of drug (if applicable)

    Time frame: At the end of Cycle 7 (each cycle is 21 days)

Other outcomes

  1. Biomarker assessment

    To evaluate the correlation between potential biomarkers and the prognosis of patients treated with this regimen. Tumor tissue or blood samples will be examined to detect the gene expression of MYD88.

    Time frame: Up to approximately 2 years

  2. Metabolite analysis of HMPL-760 in combination with R-GemOx

    Analysis metabolite of HMPL-760 in combination with R-GemOx

    Time frame: At the end of Cycle 7 (each cycle is 21 days)

07

Study locations

16 sites
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi, China
  • Wuhan Union Hospital of China
    Wuhan, Hebei, China
  • Harbin First Hospital
    Harbin, Heilongjiang, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • Shandong Cancer Hospital & Institute
    Jinan, Shandong, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Tianjin, Tianjin Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in May 2026, 18 months.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 18 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2024
First posted
Sep 19, 2024
StartActual
Nov 5, 2024
Primary completionActual
May 23, 2026
CompletionActual
May 23, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06601504
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Nov 5, 2024
Primary completion
May 23, 2026
Completion
May 23, 2026
Last update
Sep 24, 2026

Study contacts

Weili Zhao
principal investigator · Ruijin Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor HMPL-760

Start the discussion